Dr. Grothey on Treatment Landscape of mCRC

Axel Grothey, MD
Published: Tuesday, Feb 28, 2017



Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

There are a variety of different agents available for patients with mCRC currently, Grothey explains. However, a next step involves making sense of which combinations are used for which clinical setting. Additionally, treatment approaches need to be individualized since tumor histology and characteristics differ from one another. Researchers need to tailor therapies according to patient needs, Grothey adds, and utilize the treatment combinations available in the armamentarium.

Before starting treatment for a patient with palliative intent, physicians must keep in mind that the goal of palliation is to keep patients alive and have a good quality of life. When discussing treatment options with patients, Grothey says he explains treatment algorithms and plans for the future, as patients with metastatic disease will likely be on therapy for the rest of their life with breaks in between.
SELECTED
LANGUAGE


Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

There are a variety of different agents available for patients with mCRC currently, Grothey explains. However, a next step involves making sense of which combinations are used for which clinical setting. Additionally, treatment approaches need to be individualized since tumor histology and characteristics differ from one another. Researchers need to tailor therapies according to patient needs, Grothey adds, and utilize the treatment combinations available in the armamentarium.

Before starting treatment for a patient with palliative intent, physicians must keep in mind that the goal of palliation is to keep patients alive and have a good quality of life. When discussing treatment options with patients, Grothey says he explains treatment algorithms and plans for the future, as patients with metastatic disease will likely be on therapy for the rest of their life with breaks in between.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x